Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02514837 | Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer(RTM) | withdrawn | — | 0 | University of EdinburghOTHER | 0 | Aug 19, 2022 | clinicaltrials |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | withdrawn | N/A | 0 | Xoft, Inc.INDUSTRY | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04685551 |
| Improving Survivorship Among Minority Cancer Dyads |
| withdrawn |
| N/A |
| 0 |
| Charles Drew University of Medicine and ScienceOTHER |
| 1 |
| Jul 26, 2022 |
| clinicaltrials |
| NCT02569489 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | withdrawn | Phase 1 | 0 | HUYABIO International, LLC.INDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT02562612 | Study of SM-88 in Advanced Cancers | withdrawn | Phase 1 / Phase 2 | 0 | Tyme, IncINDUSTRY | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02035085 | 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction(CS-1000) | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT04630210 | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity(AteBrO) | withdrawn | Early Phase 1 | 0 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT04560439 | Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05005936 | Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT03811262 | Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery | withdrawn | N/A | 0 | University of PadovaOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03261323 | Breast Reconstruction Following Breast Cancer in Very High Risk Patients | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT05041751 | Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 17, 2022 | clinicaltrials |
| NCT05037019 | SIGNAL During a COVID-19 Pandemic | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | May 16, 2022 | clinicaltrials |
| NCT05359874 | Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW(DoT-FMI) | withdrawn | Phase 2 | 0 | Technical University of MunichOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT05156463 | The PAI Trial for Breast and Colon Cancer Survivors | withdrawn | N/A | 0 | Milton S. Hershey Medical CenterOTHER | 0 | Apr 28, 2022 | clinicaltrials |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | withdrawn | Phase 1 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients(EURO-DIGNITY) | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 3 | Apr 7, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT04856475 | Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer(NeraBrain) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Mar 2, 2022 | clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT04691999 | The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer(EFFECT-BC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer(Breast 51) | withdrawn | Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03511079 | Music as a Perioperative Therapy in Breast Cancer Patients | withdrawn | N/A | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT01714128 | FES-PET for Patients Treated on NCI Protocol 8762 | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04020523 | Advanced MR Techniques for Breast Cancer Detection(RAPIDIRM) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 20, 2021 | clinicaltrials |
| NCT04585724 | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 0 | Oct 18, 2021 | clinicaltrials |
| NCT03940248 | Proton Accelerated Partial Breast Irradiation(APBI) | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04917640 | Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT) | withdrawn | — | 0 | GenesisCare USAOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer(PANDoRA) | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04449809 | Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer(EXERT-BC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04292860 | Reverse Axillary Mapping in Breast Radiation Treatment Planning | withdrawn | — | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | May 27, 2021 | clinicaltrials |
| NCT03161834 | Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer | withdrawn | — | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04487912 | Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer | withdrawn | Phase 4 | 0 | University Hospital, GhentOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03658213 | To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.(LARES) | withdrawn | Phase 3 | 0 | AstraZenecaINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04828044 | Microwave Ablation of Breast Tumors | withdrawn | — | 0 | St. Joseph Hospital of OrangeOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03437915 | BrUOG 351: PRE-OPERATIVE APBI USING NIBB(351) | withdrawn | N/A | 0 | Jaroslaw HepelOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT03863301 | MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer(ABLATIVE-2) | withdrawn | Phase 2 | 0 | UMC UtrechtOTHER | 1 | Feb 26, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2022source: clinicaltrials